Non-Hodgkin Lymphoma Treatment Market to Reach $17.8 Billion by 2035

Non-hodgkin lymphoma treatment market was valued at $7.9 billion in 2025 and is projected to reach $17.8 billion by 2035, registering a CAGR of 8.6% from 2026 to 2035. Market growth is largely driven by the increasing global burden of cancer and the rising adoption of advanced biologics, including CAR-T cell therapies and monoclonal antibodies. According to the World Health Organization, global cancer cases are expected to exceed 35 million annually by 2050, indicating a significant rise in oncology demand. This growing patient pool is fueling the need for more effective and targeted treatment options. In addition, the rapid expansion of immunotherapies and precision medicines is transforming treatment protocols. The increasing availability of these therapies across hospitals and specialty cancer centers is further supporting market growth.

Browse the full report description of “Non-Hodgkin Lymphoma Treatment Market Size, Share & Trends Analysis Report by Therapy Class (Chemotherapy, Immunotherapy, Targeted Therapy, Cell Therapy, Others), by Disease Type (B-cell Lymphomas, T-cell Lymphomas), by End-Use Industry (Hospitals, Specialty Cancer Centers, Ambulatory Care Centers), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/non-hodgkin-lymphoma-treatment-market

Innovation Leaders Transforming the Non-Hodgkin Lymphoma Treatment Market

The key players in the non-hodgkin lymphoma treatment market include top companies such as Roche, Johnson & Johnson, Merck & Co., Pfizer, and AbbVie, among others. These companies are focusing on biologics innovation, CAR-T expansion, and targeted therapies to strengthen their market position. Increasing investments in oncology pipelines and biosimilar competition are reshaping the market landscape. Strategic collaborations and product launches are further intensifying competition.

• In November 2025, Roche announced new clinical data demonstrating improved survival outcomes with its bispecific antibody Columvi (glofitamab) in patients with relapsed/refractory diffuse large B-cell lymphoma, a key form of non-Hodgkin lymphoma. The therapy showed superior efficacy compared to standard rituximab-based regimens, supporting its growing role in advanced NHL treatment.

• In September 2024, AbbVie showcased advancements in its oncology pipeline at ESMO 2024, highlighting progress in antibody-drug conjugates and innovative cancer therapies targeting high unmet needs. While the update primarily focused on solid tumors, the underlying platform technologies support broader oncology applications, including hematologic malignancies such as lymphoma.

• In April 2024, Bristol Myers Squibb partnered with Cellares in a $380 million agreement to expand global manufacturing capacity for CAR-T cell therapies. The collaboration aims to enhance scalability and accelerate delivery of advanced cell therapies used in blood cancers, including non-Hodgkin lymphoma.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-

• By Therapy Class
• By Disease Subtype
• By End User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Roche, Johnson & Johnson, Merck & Co., Pfizer, and AbbVie, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Non-Hodgkin Lymphoma Treatment Market Report Segment

By Therapy Class

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Cell Therapy
•  Others

By Disease Type

• B-cell Lymphomas
• T-cell Lymphomas

By End User

• Hospitals
• Specialty Cancer Centers
• Ambulatory Care Center

Global Non-Hodgkin Lymphoma Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/non-hodgkin-lymphoma-treatment-market